Form 4: AN2 Therapeutics Director Gilbert Marks Acquires Shares as Non-Cash Compensation

AN2 Therapeutics Director Gilbert Lynn Marks acquired 11,875 shares of common stock on July 10, 2025, as non-cash compensation, increasing his total beneficial ownership to 53,382 shares.

Summary

• Gilbert Lynn Marks, a Director of AN2 Therapeutics, Inc. (ANTX), acquired 11,875 shares of the company's Common Stock.
• The transaction occurred on July 10, 2025.
• The shares were issued at a price of $0, representing compensation in lieu of cash under the company's non-employee director compensation policy.
• All acquired shares vested immediately upon issuance.
• Following this acquisition, Gilbert Lynn Marks beneficially owns a total of 53,382 shares of AN2 Therapeutics Common Stock.

Sentiment

Score: 6

Explanation: The filing indicates a director's acquisition of shares as part of compensation, which is a routine event. While it shows alignment of interests, it doesn't inherently signal significant positive or negative operational news.

Positives

• Director Gilbert Lynn Marks increased his beneficial ownership in AN2 Therapeutics by acquiring 11,875 shares, aligning his interests further with shareholders.
• The shares were issued as compensation, indicating a non-cash expense for the company for director services.
• All acquired shares vested immediately, providing the director with immediate full ownership.

Negatives

• No specific negatives are indicated in this Form 4 filing, as it primarily reports a routine compensation-related stock acquisition by a director.

Risks

• No specific risks are detailed in this Form 4 filing, which is a transactional report.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• No direct management comments or notable quotes are included in this Form 4 filing, which is a transactional report.

Industry Context

This Form 4 filing reports a routine insider transaction related to director compensation, which is a common practice across industries to align management interests with shareholders. It does not provide broader industry trend insights.

Comparison to Industry Standards

• This Form 4 reports a specific director's equity compensation. While director compensation practices vary, the issuance of stock in lieu of cash is a standard practice across many publicly traded companies to align director incentives with shareholder value. Specific comparable companies or projects are not relevant for this type of individual transaction report.

Related Party Transactions

• The acquisition of 11,875 shares by Director Gilbert Lynn Marks represents compensation in lieu of cash, which is a related party transaction under the issuer's non-employee director compensation policy.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

AN2 Therapeutics, ANTX, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Equity Compensation, Gilbert Lynn Marks